stockrowCapricor Therapeutics, Inc.
CAPR Healthcare Biotechnology
Capricor Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $22.3 million, down 11.5% from fiscal 2023.
- Revenue
- −7.92%
- EPS
- −22.8%
- Free cash flow
- −72.9%
Quarter to June 2026, against a year earlier
Follow CAPR
Alert me
Capricor Therapeutics, Inc. (CAPR) EV/Sales
As of 3 November 2026, Capricor Therapeutics, Inc. (CAPR) trades at a EV/Sales of 11.1×. Over the past ten years it has ranged from 0.0× (August 2026) to 601× (June 2021); the current reading is higher than 26% of that period. That is above the Biotechnology industry median of 9.5× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | 15.7× | 252.60% |
| FY2023 | 4.4× | (81.82%) |
| FY2022 | 24.4× | (84.26%) |
| FY2021 | 155× | 37.65% |
| FY2020 | 113× | 813.71% |
| FY2019 | 12.3× | (36.72%) |
| FY2018 | 19.5× | 4.76% |
| FY2017 | 18.6× | 70.36% |
| FY2016 | 10.9× | 35.69% |
| FY2015 | 8.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2024 | 15.7× | (15.90%) |
| Sep 2024 | 18.6× | 264.09% |
| Jun 2024 | 5.1× | (29.62%) |
| Mar 2024 | 7.3× | 63.62% |
| 33 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PRTCY PureTech Health PLC Sponsored ADR compare | −9.1× |
| MNPR Monopar Therapeutics Inc. compare | n/m |
| RLMD Relmada Therapeutics, Inc. compare | n/m |
| EPRX Eupraxia Pharmaceuticals Inc. compare | n/m |
| CRMD CorMedix Inc compare | 0.7× |
| ASMB Assembly Biosciences, Inc. compare | 0.8× |
| PRTA Prothena Corporation plc compare | 2.6× |
| CAPR Capricor Therapeutics, Inc. | 11.1× |
| YDES YD Bio Limited compare | — |
| Biotechnology industry median | 9.5× |
| Healthcare sector median | 3.5× |
| Market median | 2.2× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)